MedTrace Logo

Perineural Dexmedetomidine and Femoral Nerve Block

NCT01964040 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2013-10-17

No results posted yet for this study

Summary

The duration of sensory block after single dose of long acting local anesthetics is not sufficient to avoid the postoperative use of opioids. Alpha-2 adrenoceptor agonists such as clonidine have been shown to increase the duration of peripheral nerve block. Dexmedetomidine is a more potent and selective α-2-adrenoceptor compared to clonidine. To the best of our knowledge, the use of Dexmedetomidine as adjuvant to local anesthetic was not previously reported for femoral nerve block.

Conditions

  • Onset and Duration of Sensory and Motor Block of Femoral Nerve,
  • Visual Analogue Pain Scores,
  • Time to First Request of Rescue Analgesics,
  • Total Morphine Consumption in 24 Hours

Interventions

DRUG

peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block

ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously. After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia

Sponsors & Collaborators

  • anesthesia department

    collaborator AMBIG

  • faculty of medicine

    collaborator AMBIG

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2013-12-31
Completion
2014-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01964040 on ClinicalTrials.gov